Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs) using the UG3/UH3 mechanism. The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of CUDs or their consequences such as withdrawal, craving, or cannabis use relapse. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of CUDs. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.

The American Society for Radiation Oncology is accepting applications for its 2019 Minority Summer Fellowship Award. The annual program is designed to introduce medical students from backgrounds that are underrepresented in medicine to the discipline of radiation oncology early in their medical education. Although medical students in all years are encouraged to apply, preference will be given to first- and second-year students. In an effort to promote radiation oncology as a career choice, the fellowship will expose medical students to clinical, basic, and translational research questions in radiation oncology. The fellowship provides each student with a $4,500 package that includes a $3,500 stipend for the eight-week training program (exceptions can be made for a longer program but will need to be approved by ASTRO's Committee on Health Equity, Diversity and Inclusion, or "CHEDI") and $1,000 toward the cost of travel to the organization's 2019 annual meeting. To be eligible, applicants must be enrolled in a United States medical school and be able to identify a mentor with a successful record of research productivity. The mentor should be an ASTRO member. In addition, research must be undertaken at a North American institution during the summer of 2019.

Using its strength in glycoscience, the client wishes to achieve the following FCH- and s-FCH-related goals with a potential partner to continue to supply the world with innovative pharmaceuticals/medical devices in this field: Supply pharmaceuticals/medical devices that meet unmet medical needs Specialized areas/diseases: Diseases of locomotive organs, ophthalmic diseases, and diseases of the mucous membrane in the mouth, esophagus, gastrointestinal tract, etc. Supply products that cannot be replaced by other products or competitor's products, using the client's strength in glycoscience

To that end, the foundation welcomes applications for its Research Program, which supports pioneering discoveries in science, engineering, and medical research. Through the program, grants are awarded to research universities, medical colleges, and major private independent scientific and medical research institutions in support of projects that are focused on important and emerging areas of research; have the potential to develop breakthrough technologies, instrumentation, or methodologies; are innovative, distinctive and interdisciplinary; demonstrate a high level of risk due to unconventional approaches or by challenging a prevailing paradigm; and have the potential for transformative impact (e.g., the founding of a new field of research, the enabling of observations not previously possible, or the altered perception of a previously intractable problem). The program seeks to fund high-risk/high-impact work that lays the groundwork for new paradigms, technologies, and discoveries, save lives, and adds to our collective understanding of the world.

The Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) is organized into five Joint Project Management Offices (JPMO), each responsible for specific commodity areas. General information on the JPEO-CBD and subordinate JPMOs can be obtained from the JPEO-CBD website at http://www.jpeocbd.osd.mil/. The medical CBRN countermeasures developed by the Joint Project Manager Medical Countermeasure Systems (JPM MCS) office directly support the current, near-term, and far-term challenges by providing the capability to prevent, diagnose and treat the effects of chemical, radiological and biological warfare agents. Mission areas and technical points of contact for the product management offices within the JPM MCS are shown in Section VII of this BAA. Proposals are sought from all eligible sources as specified herein, including educational institutions, nonprofit organizations, and private industry. This Broad Agency Announcement (BAA) provides general information, proposal preparation instructions, evaluation and selection criteria, and award administration.

BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of Chemical, Biological, Radiological and Nuclear (CBRN) agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the 2014 PHEMCE Implementation Plan for CBRN Threats. 

Current research and education priorities of the foundation include support for early-career investigators (fellows and young faculty with less than five years post-fellowship training) and support for the development of innovative approaches to the delivery of medical toxicology education to healthcare providers and the lay public.

Current research and education priorities of the foundation include support for early-career investigators (fellows and young faculty with less than five years post-fellowship training) and support for the development of innovative approaches to the delivery of medical toxicology education to healthcare providers and the lay public.

TRANSLATIONAL MEDICINE AND THERAPEUTICS: The goal of the PhRMA Foundation's Translational Medicine and Therapeutics Program is to promote the development and use of experimental and computational methods in an integrative approach towards clinical needs in diagnosis, treatment and prevention. This can involve enhanced understanding of human biological and disease processes but requires a strong translational component. This program will support the concepts of Translational Medicine and Therapeutics as defined by the Foundation: "Translational medicine and therapeutics is a discipline focused on bridging experimental and computational technologies and discoveries in the research laboratory to their application in clinical practice. Examples of research components include activities in molecular and cellular biology, pathophysiology, systems biology, bioinformatics, modeling and simulation, and other quantitative sciences to connect basic biological concepts and entities to directly address unmet medical needs. The goals are to use clinical observation as the basis for hypothesis generation to further basic research and to efficiently advance the product of basic research to patients." Translational Medicine and Therapeutics awards will advance training and support career development of scientists engaged in research that significantly integrates cutting-edge technologies with advanced biological, chemical, and pharmacological sciences and engineering methodologies in such areas as (but not restricted to): * Genetics (Molecular, Pharmaco-, Population, Medical) * Genomics (Functional, Structural, Toxico-, Pharmaco-, Comparative) * Systems (Biology and Pharmacology) * Pathways and networks * Integrative biology * Modeling and simulation * Target Identification and Validation * Biomarker Discovery and Validation * Vaccine Development * Molecular Epidimiology * Imaging * Disease Modeling

Applicants must choose one of the following categories they feel their project best exemplifies: 1.) Outstanding Emerging Innovation: The winning nominee is a person or company working on the basic research phase of an innovation - for three years or less, pre-commercialization - that has received grant money or outside money and that demonstrates the potential for continued growth and success. 2.) Outstanding Bioscience Innovation: The winning nominee is a company that has achieved a significant milestone in the life sciences, including but not limited to drug therapeutics, medical devices, medical imaging and pharmacogenetics. 3.) Outstanding Information Technology Innovation: The winning nominee is a company that has achieved a significant milestone in information technology, including hardware and software, packaged applications, custom applications and digital media. 4.) Outstanding Marketing Innovation: The winning nominee is a company that has achieved a significant milestone in consumer marketing. 5.) Outstanding Advanced Engineering Innovation: The winning nominee is a company that has achieved a significant milestone in advanced engineering - where technology is used to design a product.

The U.S. Army Medical Research and Materiel Command's mission is to responsively and responsibly create, develop, deliver, and sustain medical capabilities for the Warfighter. The AIMM initiative was created to accelerate transformational biomedical research for our Armed Forces and Nation. The mission of the AIMM initiative is to encourage, identify, and enable innovative research that leads to cross-cutting solutions to military health threats. The AIMM Research Award is intended to support highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine. AIMM initiative funding supports novel research concepts and other efforts that initiate or enhance potential game-changers that may not be supported by other funding mechanisms or core programs.

Our goal is to connect businesses and organizations that are best-positioned to address critical needs during this public health crisis, often in innovative or unexpected ways. Then we support those businesses to do what they do best: scale products and services that can help the American public. In the immediate term, we are keenly focused on working with companies-large and small-to spur development of personal protective equipment for medical and non-medical use, novel testing solutions, widely-accessible therapeutics and health services to address the needs of underserved communities. As the crisis evolves, we will continue to be responsive by tackling other urgent priorities.

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use.Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.

The Epilepsy Foundation has announced its seventh annual epilepsy "Shark Tank" competition for the most innovative ideas in epilepsy and seizure treatment and care. Selected finalists will receive international recognition and compete for grants totaling $150,000 to support the development and commercialization of important new products, technologies, or therapeutic concepts. As many as six finalists will be selected to present at the 2018 Epilepsy Pipeline Conference (San Francisco, February 22-23, 2018). Each presenter will have five minutes to present the concept, followed by five minutes of questioning. The event will feature live voting among audience members and a panel of judges (Sharks) representative of industry, advocacy, investors, and the research and medical communities. The winning project(s) deemed to be the most innovative will be announced at the conclusion of the competition. To be eligible, applicants must demonstrate an ability to move the proposed plan to completion, showing how the prize can accelerate any step along the path to market. Inventors who submitted ideas in previous Shark Tank competitions are encouraged to re-submit their ideas if substantial progress has been made.

The American Association for Cancer Research is accepting applications for its AACR NextGen Grants for Transformative Cancer Research program. The annual program is designed to stimulate highly innovative research from young investigators. Three-year grants of up to $450,000 will be awarded in support of creative, paradigm-shifting cancer research that might not be funded through conventional channels. The funds are intended to support expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants; research/laboratory supplies and equipment; travel applicable to the research project; publication charges for manuscripts that pertain directly to the funded project; and other research expenses and indirect costs. Research projects must represent a highly innovative approach to a major contemporary challenge in cancer research. The research, which can be in any area of basic, translational or clinical science, must have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or ability to treat, detect, or prevent cancer. To be eligible, applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. In addition, at the start of the grant term on July 1, 2018, applicants must hold a tenure-eligible appointment at the level of assistant professor; have held this appointment for no more than three years; and work at an academic, medical, or research institution anywhere in the world. AACR membership is required.

Undertake research activities that would entail implementing and evaluating community-based efforts to fight the opioid overdose epidemic; and Support and promote the partnership of law enforcement and public health agencies, whose collaboration is critical to reducing overdose and other harms of opioid (mis)use. This ongoing opioid overdose epidemic presents new challenges to public health and public safety officials, medical professionals, local communities, and other stakeholders invested in curbing rates of accidental death. Preparing regional and community leaders to respond effectively to the public health emergency that is today's opioid overdose crisis (and be prepared to take on that crisis as it evolves tomorrow) is essential for achieving the shared goal of preventing fatal overdose and saving lives. ONDCP expects to award one Federal grant under the Combating Opioid Overdose through Community-Level Intervention Initiative for a 1-year period, beginning approximately September 2017. The successful non-Federal entity (NFE) will conduct research activities that entail implementing and evaluating community-based efforts to fight the opioid overdose epidemic. These activities will be focused on the regions of the United States with some of the highest rates of fatal and non-fatal opioid-related overdoses and will work to coordinate the often decentralized state and local efforts to assess and respond to opioid-related overdoses.

The purpose of this research is to identify, implement, and evaluate the use of effective strategies and tools for provider and patient use to taper and/or discontinue opioids, benzodiazepines, and other medications in which risk outweighs benefits to prevent falls, overdose, and other injuries among community dwelling older adults.

The Geobiology and Low-Temperature Geochemistry Program focuses on geochemical processes in terrestrial Earth's surface environmental systems, as well as the interaction of geochemical and biological processes. The program supports field, laboratory, theoretical, and modeling studies of these processes and related mechanisms at all spatial and temporal scales. Studies may address: 1) inorganic and/or organic geochemical processes occurring at or near the Earth's surface now and in the past, and across the broad spectrum of interfaces ranging in scale from planetary and regional to mineral-surface and supramolecular; 2) the role of life in the transformation and evolution of Earth's geochemical cycles; 3) surficial chemical and biogeochemical systems and cycles, including their modification through environmental change and human activities; 4) low-temperature aqueous geochemical processes; 5) mineralogy and chemistry of earth materials; 6) geomicrobiology and biomineralization processes; and 7) medical mineralogy and geochemistry. The Program encourages research that focuses on geochemical processes as they are coupled with physical and biological processes in the critical zone. The Program also supports work on the development of tools, methods, and models for the advancement of low-temperature geochemistry and geobiology. The Geobiology and Low-Temperature Geochemistry Program is interested in supporting transformational and cutting-edge research. The Program is highly interdisciplinary and interfaces with other programs within the Earth Surface Section and with programs in biology, chemistry and engineering.

The Howard Hughes Medical Institute (HHMI) today announced a new program to recruit and retain early-career scientists who are from gender, racial, ethnic, and other groups underrepresented in the life sciences, including those from disadvantaged backgrounds. Through an open competition, HHMI plans to select scientists early in their training to become Hanna H. Gray Fellows. Each fellow will receive funding for up to eight years, with mentoring and active involvement within the HHMI community. In this two-phase program, fellows will be supported from early postdoctoral training through several years of a tenure-track faculty position. In the first competition cycle, HHMI will select up to 15 fellows and invest a total of up to $25 million for their support over eight years.

The Competition is an effort to help reduce deaths associated with prescription opioid and heroin overdose by seeking innovative approaches to help reduce preventable harm associated with opioids. Specifically, the goal of this Competition is to spur innovation around the development of a low-cost, scalable, crowd-sourced mobile phone application that helps increase the likelihood that opioid users, their immediate personal networks, and first responders are able to identify and react to an overdose by administering naloxone, a medication that reverses the effects of opioid overdose.

Today the Foundation funds projects in medicine, life sciences and the physical sciences. Particular areas of interest include innovative medical investigations and applications, endangered animals and ecosystems, and climate change.